EGFR and non-small cell lung carcinoma: The second case is a 62‐year‐old woman, never smoker, diagnosed in 2013 with stage IV NSCLC with bone and asymptomatic brain metastases at presentation, which harbored an EGFR deletion in exon 19 and received erlotinib.